VES001 Safety and PK in Healthy Volunteers and GRN Mutation Carriers

Phase 1, randomised, double-blind trial of VES001 in frontotemporal dementia (FTD) (2 arms), sponsored by Vesper Bio. Primary endpoints: Treatment-emergent adverse events at 13 weeks, Clinically significant abnormalities in safety laboratory values at 13 weeks and 10 more. Started Oct 2023; status: completed.